MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.16
-0.01
-0.07%
Closed 16:00 07/10 EDT
OPEN
15.10
PREV CLOSE
15.17
HIGH
15.21
LOW
14.75
VOLUME
866.61K
TURNOVER
--
52 WEEK HIGH
27.82
52 WEEK LOW
9.74
MARKET CAP
1.53B
P/E (TTM)
-7.4537
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EPZM stock price target is 29.44 with a high estimate of 36.00 and a low estimate of 16.00.

EPS

EPZM News

More
Epizyme A Buy For Tazverik And Epigenetic Platform
Seeking Alpha - Article · 07/01 05:37
Insider Weekends: Harold Hamm Buys More Of Continental Resources
Seeking Alpha - Article · 06/29 06:03
Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares
Simply Wall St. · 06/28 14:31
Notable Insider Buys: Continental Resources, Fox, Groupon And More
Insider buying can be an encouraging signal for potential investors. Some C-suite insiders were among those recently adding to stakes. Biotechs, an energy company and a media giant saw insider buying.
Benzinga · 06/27 19:17
Aptinyx PTSD Trial And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/21 07:11
Dow gives up early gains as Apple says it will re-close stores and W.H.O. says coronavirus has entered new and dangerous phase
MarketWatch · 06/19 20:01
Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma
Zacks · 06/19 15:19
Epizyme's shares fall after receiving new FDA approval for cancer drug
MarketWatch · 06/19 15:02

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About EPZM

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
More

Webull offers kinds of Epizyme Inc stock information, including NASDAQ:EPZM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPZM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EPZM stock methods without spending real money on the virtual paper trading platform.